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Introduction
Elevated levels of  type I IFNs represent both a hallmark and a pathogenic mechanism of  autoimmune dis-
eases characterized by the so-called type I IFN signature, such as systemic lupus erythematosus (SLE) (1).
Plasmacytoid DCs (pDCs) are a rare subset of  circulating leukocytes primarily responsible for the sus-
tained production of  type I IFNs in SLE patients (1, 2). pDCs express TLR7, a single-strand RNA (ssRNA) 
sensor, and TLR9, a CpG-rich DNA sensor (3). These 2 receptors are segregated into endosomes to allow 
prompt recognition of  nucleic acids derived from engulfed microbes, while avoiding activation by extracel-
lular self–nucleic acids (4). However, in SLE, the formation of  complexes with autoantibodies or cationic 
peptides protect self-DNA from degradation and facilitate its transport to endosomes, where it activates 
TLR9 (5). A possible role for TLR7 activation by self-RNA has been postulated in autoimmune diseases, 
although it remains less characterized (6, 7).
MicroRNAs are short ssRNAs that exert posttranscriptional regulation of  gene expression within the cell 
cytoplasm (8). However, extracellular microRNAs are also present in virtually all biological fluids associated 
with carrier proteins, such as Ago2, which makes them resistant to degradation (9). MicroRNAs can also 
be transferred from cell to cell through extracellular vesicles (10), suggesting that they may work as intercel-
lular messengers (11). Indeed, vesicle-associated microRNAs were reported to elicit various physiological 
responses in target cells. However, the overall low concentration of  extracellular microRNAs and the reported 
low copy number per vesicle (12) raised the question of  whether extracellular microRNAs may reach the 
physiological limit of  about 1,000 copies per cell estimated to be required to mediate significant paracrine 
or endocrine gene suppression in vivo (9). Recently, an alternative mechanism of cell regulation exerted by 
extracellular microRNAs has emerged, based on their ability to induce a broad, nonspecific stimulation of  the 
innate immune responses via the induction of  proinflammatory cytokines in murine models of  cancer (13), 
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neurodegeneration (14), and graft-ver-
sus-host disease (15).
The aim of  this study was to 
investigate whether extracellular, 
exosome-delivered microRNAs may 
cause the activation of  human pDCs 
in vitro and the production of  type I 
IFNs in SLE.
Results
Exosomes from plasma of  SLE patients 
activate the secretion of  IFN-α by 
pDCs. Small extracellular vesicles 
were separated by ultracentrifuga-
tion, followed by density gradient 
separation from a pool of  plasma 
obtained from SLE patients (Table 
1) or age-matched healthy controls. 
Extracellular vesicle preparations 
were then evaluated for purity and 
titrated by colorimetric nanoplas-
monic (CONAN) assay (16), reveal-
ing equal amounts of  vesicles (not 
shown). Extracellular vesicle mor-
phology and size distribution was 
investigated by atomic force micro-
scope (AFM) (17), proving that the 
population had typical vesicular 
morphology and exosome size rang-
ing from 30–150 nm (Figure 1A) 
(18). The black background of  the 
AFM images indicates the absence 
of  any relevant nanoscale feature 
other than the EVs (with reference 
to the color code bar), confirming 
the absence of  residual contami-
nants from the separation procedure 
and the purity of  the samples (17). 
Finally, extracellular vesicles expressed specific exosomal markers (18) (Figure 1B). These results indi-
cate that the used small extracellular vesicle population is prevalently composed by exosomes and so will 
be hereafter referred to as exosomes.
Exosomes purified from SLE, but not from healthy plasma, induced the release of  IFN-α by freshly 
purified human circulating pDCs (Figure 1C). This action was reverted by chloroquine, indicating that 
endosomal acidification is required for pDC activation. This finding suggests that exosomes contain a puta-
tive ligand of  endosomal innate immune receptors expressed by pDCs, namely TLR7 and/or TLR9 (4). 
Exosomes contain proteins, lipids, and short RNAs (19), among which microRNAs account for about 76% 
of  total nucleic acids (20). Because pDCs do not bear endosomal receptors able to recognize proteins or 
lipids, but express the ssRNA receptor TLR7 (4, 13, 14, 21), our attention was focused on microRNAs. 
Equal amounts of  total microRNAs were detected in exosome preparation from healthy and SLE individu-
als using the Quant-iT RiboGreen kit (not shown). Real-time PCR amplification revealed the presence of  3 
microRNAs previously characterized for being expressed in SLE plasma (22, 23) (Figure 1D).
MicroRNAs delivered by exosomes activate the secretion of  IFN-α in pDCs. In order to further characterize the 
pDC-activating TLR ligand, amounts of  exosomes were needed that could not be obtained from patient 
samples. Therefore, we decided to switch to exosomes obtained from cell lines. After testing different cell 
Table 1. Demographic and clinical characteristics of systemic lupus erythematosus (SLE) 
patients
34 SLE patients n (%); median (range = min – max)
DEMOGRAPHIC DATA
Age in years (median age, range) 32.5 (19–44)
European descent 29 (85%)
Asian 2 (6%)
African-American 3 (9%)
Cigarette smoking 4 (12%)
Indoor working 34 (100%)
Disease duration (years) 7 (1–25)
SLE MANIFESTATIONS
Cutaneous manifestations (malar rash or/and discoid rash) 15 (44%)
Photosensitivity 16 (47%)
Oral ulcers 3 (8%)
Articular involvement (arthritis) 24 (71%)
Renal involvement 14 (41%)
Hematological involvement 10 (29%)
NPSLE 0
Serositis (pulmonary/pericardial effusion) 8 (24%)
Antiphospholipid syndrome 3 (8%)
SLEDAI-2K score 2 (0–4)
LABORATORY PARAMETERS
C3 (mg/dl) (n.v. = 80–160) 83.1 (49–83)
C4 (mg/dl) (n.v. = 10–40) 11.5 (4.8–32.5)
Anti-dsDNA (UI/ml) (n.v. < 7) 9.1 (0.1–74.9)
Positive aCL (IgG and/or IgM) 11 (32%)
Positive anti-b2GPI (IgG and/or IgM) 13 (38%)
Positive LA 8 (24%)
TREATMENT
Steroids (prednisone) 32 (94%)
Current prednisone dosage (mg/week) 33.1 (0–118.8)
Current use of HCQ at 5 mg/kg/day 27 (79%)
Immunosuppressants (azathioprine; methotrexate; cyclosporine A) 21 (62%)
NPSLE, neuropsychiatric systemic lupus erythematosus; n.v., normal value; Anti-dsDNA, anti–double-stranded 
DNA autoantibody; aCL, anticardiolipin antibodies; LA, lupus anticoagulant; Anti-b2GPI, anti–b2-glycoprotein I 
antibodies; SLEDAI-2K score, Systemic Lupus Erythematosus Disease Activity Index 2000.
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lines, we chose the keratinocyte cell line HaCaT both for the amounts of  released exosomes and because of  
their biological significance, since the skin is a major site of  pDC activation in SLE.
HaCaT-derived exosomes were characterized by AFM (Figure 2A) and for the expression of  specific 
exosomal markers (Figure 2B) (18). These exosomes recapitulated the effects of  SLE patient–derived exo-
somes (Figure 2C). MicroRNAs purified from HaCaT exosomes and complexed with a cationic liposomal 
vehicle (DOTAP) to protect them from degradation and to facilitate endocytosis (13, 21) could efficiently 
induce the secretion of  IFN-α by pDCs (Figure 2D, left panel). In this preparation, real-time PCR revealed 
the presence of  the 3 microRNAs previously detected in circulating exosomes (Figure 2D, right panel). To 
formally identify microRNAs as pDC activators and exclude other small RNAs (which may contaminate 
the microRNA fraction obtained with commercial purification kits used in Figure 2D), microRNAs were 
isolated, taking advantage of  their constitutive association with the carrier protein Ago2. Figure 2E shows 
that microRNAs immunoprecipitated with an anti-Ago2 antibody, but not with an isotype control anti-
body, were indeed able to induce IFN-α secretion by human pDCs.
Taken together, these results demonstrate that exosome-delivered microRNAs can activate the secre-
tion of  type I IFNs by pDCs.
Figure 1. Exosomes from SLE plasma activate IFN-α secretion by pDCs. (A) Representative AFM topography image of exosomes from systemic lupus 
erythematosus (SLE) plasma pools (scale bar: 500 nm; left). Particle size distribution obtained by image analysis of >1,200 round-shaped objects with a 
diameter ranging between 1 and 650 nm (5 μm × 5 μm fields, n = 6) demonstrating a prevailing exosome size (30–150 nm) (right). (B) Western blot of the 
exosome preparation showing the expression of exosome markers CD81 and CD63 and the lack of cis-Golgi matrix protein GM130 (negative control). One 
experiment out of 2 is represented; the lanes were run on the same gel but were noncontiguous. (C) pDCs from 4 donors were stimulated with exosomes 
purified from healthy or SLE plasma pools in the presence or absence of Chloroquine (CQ; 1 μM). The secretion of IFN-α was evaluated by ELISA after a 
24-hour stimulation. Data are expressed as the mean ± SEM; *P < 0.05 versus (healthy) or #P < 0.05 versus (–) by paired Student’s t test. (D) Expression of 
selected microRNAs in exosomes obtained from plasma pools of healthy and SLE patients was evaluated by real-time PCR. Results were normalized over 
spiked-in cel-miR39. Data are expressed as the mean ± SEM of 3 replicates.
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Synthetic microRNAs containing an IFN induction motif  (IIM) activate cytokine secretion by pDCs and induce 
pDC maturation. Previous work on small interfering RNAs identified an IIM (5′-UGUGU-3′) capable of  
activating the innate immune response (24). Thus, we selected microRNAs upregulated in SLE plasma 
(23) and bearing this or similar motives (IIM microRNAs: miR574, let7b, and miR21) to evaluate their 
ability to activate pDCs. MicroRNAs devoid of  this motif  were selected as negative controls (Figure 
3A), while the viral RNA40 was used as a positive control for pDC activation (21). Figure 3B shows that 
IIM-bearing microRNAs activated the secretion of  IFN-α by pDCs with a magnitude comparable with 
RNA40. This effect was observed when microRNAs were complexed with DOTAP but not when admin-
istered free into the culture media (not shown). In addition, IIM microRNAs administered at suboptimal 
concentrations cooperated in inducing a strong IFN-α secretion (Figure 3C). Consistent with this, IIM 
microRNAs induced the nuclear translocation of  IRF-7, the master transcription factor for type I IFN 
production (Figure 3D). IIM microRNAs also induced the secretion of  the proinflammatory cytokines 
TNF-α and IL-6 (Figure 3E) and the phosphorylation of  the p65 subunits of  NF-κB (Figure 3F). In addi-
tion, IIM microRNAs induced the phenotypic maturation of  pDCs, as shown by the increased expres-
sion of  CD86 (Figure 4A) and the decrease of  the BDCA-2 levels (Figure 4B). Finally, IIM microRNAs 
rescued pDC survival when cultured in the absence of  IL-3, the main growth factor for pDCs (3) (Figure 
4C), whereas IFN-α production was similarly induced regardless of  the presence of  IL-3 (Figure 4D). 
Consistent with increased survival, IIM microRNAs induced the expression of  the antiapoptotic pro-
teins BCL-xL and A1 (Figure 4E) (25). None of  these effects were observed using control, IIM-negative 
microRNAs (e.g., miR16, miR31, and miR210) (Figures 3 and 4, and data not shown).
Figure 2. Exosomal microRNAs from HaCaT-conditioned media activate IFN-α secretion by pDCs. (A) AFM topography image of HaCaT exosomes (scale bar: 
500 nm) (left); size distribution obtained by image analysis of >1,400 round-shaped objects with a diameter ranging between 1 and 650 nm (5 μm × 5 μm 
fields, n = 3) demonstrating a prevailing exosome size (30–150 nm) (right). (B) Western blot of HaCaT exosomes showing the expression of exosome markers 
Alix and CD81 and the lack of cis-Golgi matrix protein GM130 (negative control). One experiment out of 2 is represented; the lanes were run on the same gel but 
were noncontiguous. (C) pDCs were stimulated with exosomes obtained from HaCaT-conditioned media. Where indicated, pDCs were pretreated with 1 μM CQ 
for 1 hour. Data are expressed as the mean ± SEM (n = 3); *P < 0.05 versus (–) or #P < 0.05 versus “(–)Exo” by paired Student’s t test. (D, left) MicroRNAs from 
HaCaT exosomes were purified and used to stimulate pDCs. Data are expressed as the mean ± SEM (n = 4); *P < 0.05 versus (–) by paired Student’s t test. (D, 
right) Expression of selected microRNAs in exosomes obtained from HaCaT-conditioned media was evaluated by real-time PCR. Results were normalized over 
spiked-in cel-miR39. Data are expressed as the mean ± SEM (n = 3). (E) Native, Ago2-bound microRNAs were immunoprecipitated with anti-Ago2 or isotype 
control mAb, purified with a commercial microRNA enrichment kit, and used to stimulate pDCs. Data are expressed as the mean ± SEM (n = 3); *P < 0.05 
versus (isotype) by paired Student’s t test. In all the experiments, the secretion of IFN-α was evaluated by ELISA after a 24-hour stimulation.
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These results confirm the capability of  encapsulated extracellular microRNAs to induce full pDC acti-
vation and maturation.
pDC activation by synthetic IIM microRNAs is mediated by an endosomal ssRNA receptor. As previous-
ly observed with pDC activation by exosomes (Figure 1C and Figure 2C), chloroquine inhibited — in 
a dose-dependent manner — the production of  IFN-α induced by synthetic miR574 (chosen for further 
experiments as prototypic IIM microRNA), in the absence of  any toxicity as measured by pDC viability 
(Figure 5A). This result further demonstrates that endosomal acidification is functional for IFN-α secretion 
by microRNAs. In addition, fluorescent miR574 colocalized with the early endosome marker EEA1, but 
not with the late endosome marker LAMP-1 (Figure 5B), confirming the endosomal localization and sug-
gesting an interaction with an endosomal receptor. These findings strongly suggest TLR7, the only endoso-
mal ssRNA receptor present in pDCs, as the potential receptor involved.
Figure 3. Synthetic IIM microRNAs activate human pDCs to secrete IFN-α and proinflammatory cytokines. (A) Sequence of synthetic microRNAs. The 
IFN induction motif (IIM) is boxed, while a similar motif is dashed. The relative content of GU and U are also indicated. (B) pDCs were stimulated with 
viral RNA40 or with the indicated microRNAs (10 μg/ml) or with vehicle alone (–) for 24 hours. The production of IFN-α was evaluated by ELISA in cell-free 
supernatants. Data are expressed as mean ± SEM (n = 4–6); *P < 0.05 versus (–) by 1-way ANOVA with Dunnett’s post-hoc test. (C) pDCs were stimulated 
with a suboptimal concentration of active microRNAs (2.5 μg/ml) alone or in combination. IFN-α production was evaluated by ELISA. Data are expressed 
as mean ± SEM (n = 3); *P < 0.05 versus (–) by 1-way ANOVA with Dunnett’s post-hoc test or #P < 0.05 by Tukey’s multiple comparison test. (D) pDCs were 
stimulated with 10 μg/ml microRNAs for 4 hours. Cell membrane was identified by an anti–MHC class II–Alexa 488 (green) mAb and the nucleus by DAPI 
staining (blue). IRF-7 nuclear translocation was visualized by a specific anti–IRF-7 Ab (red). The figure shows 1 representative donor out of 3; scale bars: 
5 μm. (E) pDCs were stimulated as in B, and the production of TNF-α and IL-6 was evaluated by ELISA in cell-free supernatants. Data are expressed as 
mean ± SEM (n = 4–6); *P < 0.05 versus (–) by 1-way ANOVA by Dunnett’s post-hoc test. (F) pDCs were stimulated with miR574 for 90 minutes, lysed, and 
analyzed by Western blot using an anti–phosphorylated NF-κB p65 mAb. Image depicts 1 representative fluorogram out of 3 performed.
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TLR7, similarly to other TLRs, undergoes desensitization upon repeated stimulation (7). Accordingly, 
a 24-hour prestimulation with R848 completely blocked IFN-α production by a second R848 stimulation 
(Figure 5C). The release of  IFN-α by R848 was also dose-dependently inhibited by the pretreatment with 
miR574, but not with miR210, suggesting that miR574 and R848 engage the same receptor (Figure 5C). 
This hypothesis was further supported by the ability of  R848 to desensitize the action of  miR574 (Figure 
5D). As expected, miR574 pretreatment blocked IFN-α production by miR574 itself  (Figure 5D)
Human TLR7 is a microRNA sensor in human pDCs. To formally demonstrate the ability of  human TLR7 
to sense IIM microRNAs, experiments were performed in HEK-293 cells stably transfected with human 
TLR7, TLR8, and TLR9 and containing a NF-κB reporter gene. Figure 6A shows that IIM microRNAs, 
similarly to imiquimod, stimulated TLR7-expressing cells. As expected (13), IIM microRNAs also potently 
activated NF-κB in transfectants expressing TLR8 (Figure 6B) but not cells expressing TLR9 (Figure 6C).
Altogether, these results support the hypothesis that extracellular microRNAs activate human pDCs 
via TLR7 triggering.
Discussion
Our study reports several new findings that identify exosome-delivered microRNAs as new potential play-
ers in the pathogenesis of  human autoimmune diseases depending on excessive type I IFN production.
First, we show that exosome-delivered microRNAs activate the secretion of  type I IFNs by pDCs and 
that this effect is enhanced in SLE patients. SLE is the prototype of  the growing family of  autoimmune 
Figure 4. Synthetic IIM microRNAs induce pDC maturation and promote pDC survival. (A and B) pDCs were stimulated with the indicated microRNAs 
(10 μg/ml) or with vehicle alone (–) for 24 hours. The surface expression of CD86 (A) and BDCA-2 (B) was evaluated by FACS analysis. Data are 
expressed as the mean ± SEM of the percentage of positive cells (left y axis), as well as the mean ± SEM of the median fluorescence intensity (MFI) 
of positive cells (right y axis) normalized over unstained controls (n = 3); *P < 0.05 versus (–) by 1-way ANOVA with Dunnett’s post-hoc test. (C) 
pDCs were stimulated as indicated in culture medium devoid of IL-3 for 24 hours. Cell viability was evaluated by propidium iodide staining (mean 
SEM; n = 3); *P < 0.05 versus (–) by paired Student’s t test. (D) pDCs were stimulated with the indicated microRNAs (10 μg/ml) in the presence or 
absence of IL-3 for 24 hours. IFN-α production was evaluated by ELISA. Data are expressed as mean ± SEM (n = 3); *P < 0.05 versus (–) by paired 
Student’s t test. (E) pDCs were stimulated as indicated or lysed immediately after purification (fresh). The expression of BCL-xL, A1, and β-actin 
were determined by Western blot. One representative fluorogram out of 3 performed is shown.
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diseases known as type I IFN–dependent autoimmune diseases, in which undue pDC activation represents 
a major leading event (1). In addition to many genetic alterations clustering in the TLR and type I IFN 
pathways described in SLE individuals (26), the disease also recognizes environmental and inflammatory 
triggers (27). It is long known that, in the amplification phase of  SLE, pDC activation is sustained by 
immunocomplexes of  anti–nucleic acid antibodies (1). By contrast, self-ligands responsible for pDC activa-
tion at disease onset have only recently begun to emerge (1, 5). Our results now identify microRNAs as new 
pDC-activating molecules, setting the bases for future work to demonstrate a possible pathogenic role of  
microRNA-dependent pDC activation in murine models of  type I IFN–dependent autoimmune diseases. 
MicroRNAs represent ideal candidates in virtue of  the fact that they are released by virtually all cells in the 
body, are resistant to degradation, and were described to be deregulated in SLE and in other autoimmune 
diseases (22, 23, 28).
From a molecular point of  view, our work demonstrates that extracellular microRNAs represent poten-
tially novel endogenous ligands of  human TLR7, the unique endosomal ssRNA receptor expressed by pDCs. 
The activation of  endosomal TLRs by extracellular microRNAs was first reported by Fabbri and coworkers, 
who described the proinflammatory activation of  murine macrophages by selected microRNAs aberrantly 
secreted by cancer cells, ultimately leading to tumor growth and metastasis (13). These authors identified 
murine TLR7 as the receptor involved in microRNA sensing, a finding independently confirmed by another 
Figure 5. Synthetic IIM microRNAs localize within early endosomes and antagonize the TLR7 ligand R848. (A) pDCs were pretreated with increasing concen-
trations of CQ for 1 hour and then stimulated with miR574 (10 μg/ml) for 24 hours. The secretion of IFN-α was evaluated by ELISA (left y axis) and cell viability 
by propidium iodide staining (right y axis). Data are expressed as mean ± SEM of the percentage of IFN-α production or the percentage of live cells (n = 3); *P 
< 0.05 versus (0 µm CQ) by 1-way ANOVA with Dunnett’s post-hoc test. (B) pDCs were stimulated with 10 μg/ml miR574–Alexa 488 for 90 minutes. After fixa-
tion and permeabilization, pDCs were stained with an anti–early endosome antigen 1 (EEA1) mAb (red) or an anti–LAMP-1 Ab (red) and DAPI (blue). The image 
depicts results obtained with 1 representative donor out of 3; scale bars: 5 μm. (C) pDCs were pretreated (0h) with the indicated concentration of microRNAs 
or 1 μg/ml R848 for 24 hours, washed, and restimulated with 1 μg/ml R848 for an additional 5 hours. The production of IFN-α was evaluated by ELISA in 
cell-free supernatants. Data are expressed as the mean ± SEM of the percentage of IFN-α production (n = 4); *P < 0.05 versus (0 µm CQ) by 1-way ANOVA with 
Dunnett’s post-hoc test. (D) pDCs were pretreated (0h) with R848 (1 μg/ml) or miR574 (10 μg/ml) or left untreated for 24 hours, washed, and restimulated 
with miR574 for additional 24 hours. IFN-α was measured by ELISA in cell-free supernatants. Data are expressed as the mean ± SEM (n = 3); *P < 0.05 versus 
(–) by 1-way ANOVA with Dunnett’s post-hoc test.
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group in a model of  neuronal degeneration (14). Human TLRs involved in microRNA sens-
ing were scarcely investigated. Our results now confirm that microRNAs activate human 
TLR8 transfectants, in line with previous evidence demonstrating the activation of  TLR8-ex-
pressing conventional DCs in the presence of  extracellular microRNAs (13, 15). In addition, 
using both pDCs as a physiological model of  TLR7-expressing cells and TLR7 transfec-
tants, we demonstrate that human TLR7 is a microRNA receptor. Our results also show 
that pDC-activating capability is not shared by all microRNAs. In this regard, we observed 
a strong correlation between IFN-α production and the presence of  IIM motifs. Indeed, 
miR574, containing several IIMs, turned out to be the most potent stimulator, while all 
microRNAs devoid of  IIM did not activate pDCs. In addition to IIM, other sequences, such 
as GU-rich elements or the number of  U ribonucleotides, were described to be important for 
innate immune activation by ssRNAs (13, 14, 21, 29). In accordance, the IIM microRNAs 
used here are also rich in G and U ribonucleotides. According to a recently published analy-
sis, G and U represent the most abundant ribonucleotides in human microRNAs, often pres-
ent as GU dinucleotide, and at least 50 IIM microRNAs exist (30). Thus, it is conceivable 
to assume that, in vivo, many exosomal microRNAs possess the structural features required 
to stimulate pDCs. Such redundancy may overcome the theoretical limit to microRNA-de-
pendent cell-to-cell regulation raised by the low levels of  extracellular microRNAs, as also 
suggested by our experiments using combinations of  activatory microRNAs at suboptimal 
concentrations. Of note, in our exosomal preparations, we could detect the expression of  
IIM microRNAs previously described as upregulated in SLE patients that possess the capa-
bility to activate pDCs in vitro.
The mechanisms underlying extracellular microRNA delivery and action on target 
cells remain poorly understood. Rettig and colleagues demonstrated that nanoparticles are 
selectively phagocytosed by pDCs (31), suggesting that exosome contents may be direct-
ly brought into contact with endosomal TLRs. Our results demonstrate that microRNAs 
protected by a liposomal vehicle effectively reach the endosome and recapitulate pDC acti-
vation observed using exosomes. In our hands, microRNAs administered to pDCs in the 
absence of  liposomal vehicles did not induce IFN-α secretion. This is in line with the prevailing view that 
vesicle-associated microRNAs are responsible for cell-to-cell communications, while free microRNAs may 
represent cell byproducts devoid of  biological function, although it was reported that free synthetic microR-
NAs may induce inflammatory neuronal activation (14). In addition, it was also shown that Ago2-bound 
microRNAs may enter the cells via the binding to neuropilin-1 (32). Of  note, neuropilin-1 is expressed at 
very high levels by pDCs (1) and may, thus, allow the internalization of  native, Ago2-bound microRNAs in 
our cell type. Further work is needed to investigate this possibility.
In summary, our work demonstrate that (a) exosomes purified from the plasma collected from SLE 
patients but not healthy donors, as well as microRNAs extracted from exosomes, induce the production of  
type I IFNs in human pDCs; (b) IIM microRNAs act as human pDC survival factors and activate the mat-
uration and the production of  IFN-α and proinflammatory cytokines by pDCs; and (c) IIM microRNAs 
represent potentially novel endogenous ligands of  human TLR7, the unique endosomal ssRNA receptor 
expressed by pDCs. These results highlight the induction of  type I IFN secretion by pDC as a new mecha-
nism by which extracellular microRNAs modulate the inflammatory and adaptive immune response.
Methods
Patients. Thirty-four premenopausal SLE patients were enrolled at the Department of  Clinical and 
Experimental Sciences in Brescia. Patients met the 1997 American College of  Rheumatology crite-
ria for SLE (33), and their main clinical and demographic features are presented in Table 1. To be 
Figure 6. Synthetic IIM microRNAs engage human TLR7. (A–C) HEK-293 cells stably transfected with 
human TLR7 (A), TLR8 (B), or TLR9 (C) were stimulated with 10 μg/ml of the indicated microRNAs 
or vehicle alone (–) for 24 hours. Imiquimod (1 μg/ml) or CpG-B (10 μg/ml) were used as TLR-specific 
positive controls. NF-κB activation was evaluated in terms of fold luciferase activity over unstimu-
lated cells. Data are expressed as the mean ± SEM (n = 3–4); *P < 0.05 versus (–) by 1-way ANOVA 
with Dunnett’s post-hoc test.
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included in the study, patients had to be on stable disease inactivity, defined as absence of  SLE flare 
and Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score (34) below 6 in 
the year prior to enrollment.
Cell preparation and culture. Peripheral blood mononuclear cells (PBMCs) were obtained from buffy coats 
(through the courtesy of  Centro Trasfusionale, Spedali Civili, Brescia, Italy) by Ficoll gradient. Peripheral 
blood pDCs were obtained after a immunomagnetic separation with the Plasmacytoid Dendritic Cells Iso-
lation kit II (Miltenyi Biotec). pDCs (1 × 106 cells/ml) were cultured in RPMI 1640 (Gibco, Thermo Fisher 
Scientific), supplemented with 10% heat-inactivated FBS, 2 mM L-Glutamine, penicillin and streptomycin 
(Gibco), and 20 ng/ml IL-3 (Miltenyi Biotec) (35). Human HaCaT cell line (CLS) was cultured in DMEM 
supplemented with 10% FBS.
Stimulation of  peripheral blood pDCs. Purified pDCs were stimulated with 10 μg/ml synthetic RNA oli-
gonucleotide RNA40 or synthetic microRNAs (listed in Figure 3A; all bases depict a phosphorothioate 
linkage) synthesized by Integrated DNA Technologies (IDT). Complexation of  RNA or microRNA with 
DOTAP Liposomal Transfection Reagent (Roche Diagnostics) was performed according to the manufac-
turer’s recommendation. Briefly, 5 μg RNA or microRNA in 50 μl HBS buffer (20 mM HEPES, 150 mM 
NaCl, pH 7.4) was combined with 100 μl DOTAP solution (30 μl DOTAP plus 70 μl HBS buffer) and 
incubated for 15 minutes at 20°C. DOTAP/RNA (50 μl) or microRNA mixture were used for stimulation 
of  a 96-well that contained pDCs in 100 μl complete medium. Where indicated pDCs were stimulated with 
TLR7 agonist R848 (1 μg/ml; InvivoGen) or pretreated with Chloroquine (InvivoGen) (36).
Cytokine measurement. IFN-α in culture supernatants was detected using a specific Module Set ELISA 
kit (eBioscience, Affymetrix). IL-6 and TNF-α were measured using specific Duo-Set kits (R&D Systems).
Exosome isolation from plasma and HaCaT conditioned media. To obtain conditioned media for exosome 
isolation, HaCaT cells were grown in complete DMEM until the reach of  70% confluence, and then the 
media were removed and renewed with DMEM without FBS for 48 hours. Afterward, conditioned media 
were collected and processed with a serial centrifugation protocol (37, 38). Briefly, conditioned media were 
centrifuged firstly at 800 g for 30 minutes to pellet and discard possibly contained apoptotic bodies and 
cellular debris. The supernatant was then centrifuged at 16,000 g for 45 minutes to pellet microvesicles and 
ultracentrifuged at 100,000 g for 2 hours to collect exosomes (Type 45 Ti rotor, Beckman Optima XPN 80, 
Beckman Coulter). Exosomes were washed with 1 ml of  sterile PBS buffer to remove protein-based con-
taminants and pelleted at 100,000 g for 2 hours. Each centrifugation step was performed at 4°C.
To isolate exosomes from plasma samples, 8 ml of  plasma derived from a pool of  SLE patients or 
healthy donors were processed by serial centrifugations followed by gradient centrifugation. Briefly, exo-
some fraction was resuspended in 800 μl buffer (10 mM Tris–HCl 250mM sucrose, pH 7.4) and processed 
by a discontinuous sucrose gradient made by 6 fractions (15%, 20%, 25%, 30%, 40%, 60% sucrose in 
10 mM Tris–HCl, pH 7.4) and centrifuged at 100,000 g for 16 hours (rotor MLS 50, Beckman Optima 
MAX). Twelve fractions with equal volumes (400 μl) were collected from the top of  the gradient. The 
exosomes contained in fractions from 6–9 were pelleted by ultracentrifugation (100,000 g for 2 hours). 
Exosomes were evaluated for purity and titrated by CONAN assay as previously described (16). The total 
RNA content was calculated using the Quant-iT RiboGreen kit (Thermo Fisher Scientific) according to 
the manufacturer’s instructions.
AFM imaging of  exosomes. Exosomes isolated from HaCaT conditioned media or plasma pools were 
resuspended in 100 μl of  PBS and diluted 1:100 with sterile Milli-Q water (MilliporeSigma). The diluted 
sample (5–10 μl) was then spotted onto freshly cleaved mica sheets (Grade V-1, thickness 0.15 mm, size 15 
× 15 mm2). The samples were then air dried over a plate heated at 37°C–40°C for 20 minutes. They were 
finally imaged with a NaioAFM (Nanosurf  AG) equipped with ContAl-G (Budget Sensors). Images were 
acquired in contact mode, with a scan size ranging from 2.5–25 μm and a scan speed from 0.8–1.2 seconds 
per scanning line. Size distribution analysis of  the deposited exosomes was performed with the software 
WSxM 4.0 image (39). For the AFM size distribution analysis, topography images with an image scan 
size of  5 × 5 μm were used. A minimum of  1,200 round-shaped vesicles with a diameter ranging between 
30 nm and 650 nm were analyzed. Obtained data were grouped in 50-nm classes, and off-scale and non-
round-shaped objects were excluded from the analysis.
Immunofluorescence. For the assay of  the nuclear translocation of  IRF-7, purified pDCs were stim-
ulated for 4 hours with synthetic microRNAs (10 μg/ml). After incubation, cells were stained with 
an anti–human MHC class II-Alexa Fluor 488 (307619, BioLegend) and subsequently fixed overnight 
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with 1% paraformaldehyde, seeded on glass slides by cytospin, and permeabilized with 100% ice-cold 
methanol (MilliporeSigma) for 10 minutes at –20°C. Samples were labeled with a rabbit polyclonal 
anti–human IRF-7 antibody (sc-9083, Santa Cruz Biotechnology Inc.). A conjugate Alexa Fluor 594 
anti-rabbit (A-11072, Thermo Fisher Scientific) was used as a secondary antibody (40).
For visualization of  the trafficking of  microRNA to endosome, pDCs were incubated with Alexa Fluor 
488–tagged miR574 for 90 minutes. Cells were fixed overnight with 1% paraformaldehyde (MilliporeSig-
ma), seeded on glass slides by cytospin, and permeabilized with 0.2% Triton X-100 (MilliporeSigma) for 
10 minutes at RT. pDCs were labeled with a mouse monoclonal anti–human EEA1 antibody (610456, BD 
Biosciences) or with a rabbit polyclonal anti–human LAMP-1 antibody (ab24170, Abcam), and an Alexa 
Fluor 594 anti-mouse (A-21203, Thermo Fisher Scientific) or an Alexa Fluor 594 anti-rabbit were used as 
secondary antibodies, respectively.
Glass slides were mounted using Prolong antifade with DAPI (Thermo Fisher Scientific). Cell imaging 
was performed with a ZeissAxio Observer Z1 microscope equipped with Apotome system and a Plan-Apo-
chromat 100×/1.4 NA oil objective.
FACS analysis. pDCs were stained with Vioblue-conjugated anti-CD86 (clone FM95, Miltenyi Biotec) 
and APC-conjugated anti–BDCA-2 (clone AC144, Miltenyi Biotec) after 24 hours of  the indicated treat-
ments. Samples were read on a MACSQuant Analyzer (Miltenyi Biotec) and analyzed with FlowJo (Tree 
Star Inc.). To assess cell viability, pDCs were stained with Propidium Iodide (Thermo Fisher Scientific).
SDS-PAGE and Western blot. Following the indicated stimulations, pDCs were lysed in NP-40/Triton 
lysis buffer (10 mM Tris-HCl, pH 7.9; 150 mM NaCl; 0.6% NP-40; and 0.5% Triton X-100) supplemented 
with inhibitors (1 mM Na3OV4, 2 mM DTT, 1 mM NAF, 1 mM PMSF, and protease inhibitor cocktail; all 
reagents were purchased from MilliporeSigma). Equal amounts of  extracts were analyzed through SDS-
PAGE followed by Western blotting with antibodies against BCL-xL (2764, Cell Signaling Tecnologies), 
A1 (14093, Cell Signaling Technology), pNF-κB p65 (Ser536, 3033, Cell Signaling Technology), NF-κB 
p65 (sc-372, Santa Cruz Biotechnology Inc.), and β-actin (sc-47778, Santa Cruz Biotechnology Inc.) (41).
Exosome preparations from plasma pools or HaCaT conditioned media were lysed in NP-40/Triton 
lysis buffer. Extracts (20–30 μg)were analyzed through SDS-PAGE, followed by Western blotting with anti-
bodies against GM130 (610822, BD Biosciences), Alix (sc-53539, Santa Cruz Biotechnology Inc.), CD63 
(CBL553, MilliporeSigma), and CD81 (sc-166029, Santa Cruz Biotechnology Inc.).
Protein bands were detected with SuperSignal West Pico Chemiluminescent Substrate (Pierce).
NF-κB luciferase reporter assay. TLR-specific activation assays were performed using human HEK-
293 cells expressing luciferase under control of  the NF-κB promoter and stably transfected with human 
TLR7, TLR8, and TLR9. HEK-293–transfected cells were maintained in DMEM supplemented with 
10% FBS, and appropriate antibiotics were added. All the HEK-293–transfected cells were provided 
by U. D’Oro (GSK, Siena, Italy). For the NF-κB luciferase assay, 25,000 cells were seeded in complete 
DMEM without antibiotics in 96-well plates for 24 hours. Cells were stimulated with 10 μg/ml syn-
thetic microRNAs, 1 μg/ml imiquimod (TLR7 agonist), 1 μg/ml R848 (TRL7-8 agonist), and 10 μg/
ml CpG-B (TLR9 agonist) (all from Invivogen) for 24 hours. After stimulation, cells were lysed using 
ONE-Glo EX Luciferase Assay System (Promega) and assayed for luciferase activity using the EnSight-
Multimode Plate Reader (PerkinElmer).
Isolation of  microRNA-enriched fraction and Ago2-associated microRNAs. MicroRNAs contained in exo-
somes were purified with miRNeasy Mini Kit, together with RNeasy Mini Elute Cleanup Kit (Qiagen), 
according to the manufacturer’s instructions. Where indicated, 5 pg of  synthetic miR39 from Caenorhabditis 
elegans (cel-miR39) were added as a spike-in control for purification efficiency. Alternatively, microRNAs 
were immunoprecipitated from protein lysates with 10 μg of  anti-Ago2 antibody (clone 11A9, MilliporeSig-
ma) or isotype control overnight at 4°C. To capture the immune complexes, anti–rat IgG agarose (ab7020, 
Abcam) was added to the antibody/lysate samples and incubated for 2 hours at 4°C. Immune complexes 
were washed 2 times with washing buffer (50 mM Tris-HCl; 150 mM NaCl; 1 mM PMSF), and the resin 
was dissolved in 700 μl of  Qiazol reagent (Qiagen).
After purification, microRNA-enriched fraction and Ago2-associated microRNAs were complexed to 
DOTAP and used to stimulate pDCs.
MicroRNA expression analysis. A fixed volume of  3 μl of  microRNA fraction from 14-μl eluates obtained 
after microRNA isolation was used as an input into a reverse transcription reaction. Reverse transcrip-
tion was performed using miScript II RT Kit (Qiagen). The levels of  hsa-miR574, hsa-miR21, hsa-miR16, 
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AND cel-miR39 were measured using specific miScript Primer assay in association with miScript SYBR 
Green PCR Kit (Qiagen) according to manufacturer’s instructions. Reactions were run in triplicate on a 
StepOne Plus Real-time PCR System (Applied Biosystems), and the generated products were analyzed by 
the StepOne Plus Software (Version 2.3, Applied Biosystem). Cel-miR39 was used for the normalization 
of  microRNA levels.
Statistics. Statistical significance among the experimental groups was determined using paired 2-tailed 
Student’s t test, 1-way ANOVA with Dunnett’s post-hoc test, or Tukey’s multicomparison test as appropri-
ated (GraphPad Prism 7, GraphPad Software). P < 0.05 was considered significant.
Study approval. The study was approved by the local institutional ethics committee in Brescia and con-
ducted in accordance with the Declaration of  Helsinki. Patients gave their written informed consent.
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